Dana-Farber/Boston Children's was the first hospital in New
England to offer MIBG therapy (metaiodobenzylguanidine) to treat
high-risk neuroblastoma (including relapsed or
refractory neuroblastoma) and is currently one of only about 10 hospitals in
the country to provide this therapy.
Metaiodobenzylguanidine (MIBG) is a compound that can be
combined with radioactive iodine (I-131) to deliver targeted radiation therapy.
Originally developed as a blood pressure medication, oncologists began using it
more recently to deliver targeted radiation to neuroblastoma. I-131 MIBG is
administered to a child through an intravenous line and absorbed by tumor cells,
which are killed by radiation emitted by the radioactive I-131. This therapy
destroys tumors while sparing normal, healthy tissue. MIBG therapy is generally
more effective, less painful, and requires less time in the hospital than other
Learn more about how MIBG
therapy is used to treat neuroblastoma on the Dana-Farber Cancer Institute website.
Phone: 617-632-5508Online form: Request an appointment
Suzanne Shusterman, MD, describes MIBG therapy, a treatment for neuroblastoma.